Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions

Wed, 05/25/2011 - 11:20am

New Interim Results from the PRESERVE Study Evaluate ENBREL Therapy in Patients with Moderately Active Rheumatoid Arthritis

Analysis of Ankylosing Spondylitis Trials Suggests Nocturnal Back Pain is Predictive of Fatigue, and ENBREL was Shown to Reduce These Symptoms

PRISTINE Trial Data Explore Effects of ENBREL on Cardiometabolic Biomarkers in Subjects with Moderate-to-Severe Plaque Psoriasis

THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire via COMTEX/—Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (PsO), and psoriatic arthritis (PsA), will be published at two global medical congresses, the European League Against Rheumatism (EULAR) and World Congress of Dermatology (WCD), this week.

Read the rest of this entry



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.